Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...

This collaboration opens the door for further opportunities, as Scorpius expects to expand its services to include additional analytical work and future GMP manufacturing upon completion of this ...

A South Bay biotech firm has bought a big San Jose office and research building in a deal that could enable the life sciences firm to expand its local operations considerably. Vibrant Wellness has ...

Bob Duggan, 80, has gone from baking cookies to building robots, investing in biotech companies, and ranking among the ...

Explore Estonia’s biotech scene with 7 pioneering companies across Tallinn, Tartu, and beyond, fueled by top science parks ...

2024年9月13日，是生物科技股首次公开募股（IPO）异常繁忙的一天，纳斯达克同时迎来了Bicara Therapeutics、Zenas BioPharma和MBX Biosciences三家公司的上市，共筹集了7亿多美元。

Anima Biotech, the Tech.Bio leader in Visual Biology for drug discovery, will showcase its Lightning AI platform at the 3 rd annual AI/ML-Enabled Drug Discovery Session, “Leveraging GenAI to Improve ...

On September 20, 2024, Viking Global Investors, under the leadership of Andreas Halvorsen (Trades, Portfolio), made a ...

英矽智能创始人兼首席执行官Alex Zhavoronkov博士表示：“ ...

周一，Piper Sandler基于CARTITUDE-4 III期研究数据的公布，维持对Legend Biotech Corp.（纳斯达克股票代码：LEGN）的增持评级和90.00美元的目标价。该研究结果在国际骨髓瘤学会会议上公布，显示由Legend Biotech开发的CARVYKTI治疗方案与PVd/DPd治疗相比，将复发或难治性多发性骨髓瘤（r/rMM）患者的死亡风险降低了45%。

专注于生物制品的生物技术公司NKGen Biotech, Inc.面临着可能从纳斯达克全球市场摘牌的风险，原因是其股价未能达到最低投标价格要求。2024年9月23日，该公司收到纳斯达克的通知，称其普通股连续30个交易日的收盘价低于每股1.00美元的要求。 根据纳斯达克的规则，NKGen Biotech有180天的时间，即到2025年3月24日，来重新达到合规要求。如果公司股价连续至少10个交易日收 ...